司库奇尤单抗诱发一名银屑病患者出现汗疱疹。

Secukinumab-induced pompholyx in a psoriasis patient.

作者信息

Eichhoff Gerhard

机构信息

Dermatology Service Capital and Coast District Health Board, Wellington.

出版信息

Dermatol Online J. 2020 Apr 15;26(4):13030/qt3669k149.

PMID:32621689

Abstract

With a prevalence of up to 20%, eczematous lesions are the most common skin adverse events of tumor necrosis factor alpha inhibitors. Eczematous lesions triggered by more modern biologics such as the IL17A antagonist secukinumab have been rarely reported. Herein, a case of secukinumab-induced pompholyx in a psoriasis patient is presented.

摘要

湿疹样病变的发生率高达20%，是肿瘤坏死因子α抑制剂最常见的皮肤不良事件。由更现代的生物制剂如IL17A拮抗剂司库奇尤单抗引发的湿疹样病变鲜有报道。本文报告1例银屑病患者使用司库奇尤单抗后发生汗疱疹的病例。